Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma
- 1 September 1988
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 14-14 (7-8), 349-351
- https://doi.org/10.1007/bf00254382
Abstract
Forty-nine patients were treated with either 3×75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.This publication has 8 references indexed in Scilit:
- Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostateEuropean Journal of Nuclear Medicine and Molecular Imaging, 1986
- SR-89 THERAPY FOR THE PAIN OF OSSEOUS METASTASES1985
- Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma.Radiology, 1983
- Die Yttrium-90-Therapie von KnochenmetastasenDeutsche Medizinische Wochenschrift (1946), 1982
- 89Strontium therapy of bone metastases of carcinoma of the prostatic glandEuropean Journal of Nuclear Medicine and Molecular Imaging, 1979
- Serial Bone Scintigraphy for Assessing the Effectiveness of Treatment of Osseous Metastases from Prostatic CancerNuklearmedizin-Nuclear Medicine, 1978
- [Internal radiotherapy using strontium-89 in metastases-induced pain].1977
- Results of 89 Strontium Therapy in Patients with Carcinoma of the Prostate and Incurable Pain from Bone Metastases: A Preliminary ReportJournal of Urology, 1976